Information for Oncologists
Dako reagents have been your pathologist’s test-of-choice for over 30 years providing consistent reproducibility, high sensitivity in detecting early disease, and specificity for accurately defining a diagnosis.
The Dako demanding standards for clinical robustness means we are the industry leader with the most predictive tests for determining treatment decisions including: HercepTest and FISH HER2 for Herceptin, ER/PR for hormone Therapy, Topo2 for chemotherapy resistance therapy and cKIT for identifying GIST patients who will benefit from Gleevec.
Confidence in evidence based tests
Dako developed the first HER2 for selection of Herceptin patients and has over 10 years experience developing predictive diagnostics with FDA approved, clinical efficacy data guiding patient selection for drugs such as Herceptin, Gleevec, Erbitux, Tamoxifin and Chemotherapy regimens. Request Dako pharmacodiagnostics for clinically validated results.
Minimize delays for pathology reports
High quality Dako reagents minimize test re-runs delivering more rapid pathology reports to your desk. Oncologists can schedule patients sooner to begin treatment discussions with your patients. Dako products provide more prompt and definitive pathology reports, resulting in more responsive patient care.
Security in Reliable results
Dako has a long 35 year history of developing the highest quality cancer diagnostic tests with clinically validated results guiding oncologists to optimal treatment. All tests meet the most robust international standards for quality including: FDA standards for clinical accuracy, reproducibility, CE Mark, ISO13485. In addition, all Dako products receive strict quality testing prior to release to any pathology lab in the world.